Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Eric Low, Chief Executive of Myeloma UK, discusses recent advances in the development of new drugs for the treatment of patients with multiple myeloma and emphasises the importance of determining the cost effectiveness of new therapeutic approaches to ensure patient access.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.